Titan Medical Announces Intellectual Property Portfolio Expansion with Issuance of Robotic Surgery Patents Related to Camera ...
17 September 2020 - 10:00PM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(Nasdaq: TMDI), a medical device company focused on the design
and development of single-port robotic surgical technologies,
announces that it has recently been issued two U.S. patents,
increasing its global intellectual property portfolio to 58 issued
patents and 84 patent applications. The Company has also received
notices of allowance in 17 other patent applications and
accordingly anticipates their issuance in the coming months.
Included in the recent patent issuances is U.S. Patent No.
10,772,703 titled “Methods and apparatuses for positioning a camera
of a surgical robotic system to capture images inside a body cavity
of a patient during a medical procedure” and U.S. Patent No.
10,758,311 titled “Hand controller apparatus for gesture control
and shared input control in a robotic surgery system.” The ‘703
patent is directed at the autonomous positioning of a camera in
response to the location of a surgical instrument while the ‘311
patent is directed at a novel robotic hand controller with an
integrated gesture control pad used to control one or more robotic
functions, including camera control. The notices of allowance cover
various aspects of robotic surgery instrumentation, autonomous
error correction, imaging sensors, visual illumination, graphical
user interfaces and sterile barriers, and include a range of
countries and regions including the United States, Europe, China,
Japan, Australia and Canada.
“I commend Jasminder Brar, our Vice President of Legal, IP and
Strategic Initiatives, for his leadership and foresight in
formulating an intellectual property strategy that continues to
create significant value for Titan’s stakeholders. As evidenced by
our recent strategic announcements, intellectual property is
fundamental to Titan’s success, providing a foundation to product
commercialization, mitigating against certain risks, protecting the
company’s innovations and facilitating value creation,” said David
McNally, President and CEO of Titan Medical Inc. “While we are
always excited to obtain new patents and allowances, the issuance
of these recent patents is especially exciting as they relate to
human-machine interaction, an area where we have paid special
attention in advancing the ergonomic friendliness of medical
robotics based on feedback from surgeons.”
The Company is also excited to share that Mr. Brar has been
recognized by Intellectual Asset Management (IAM) as a global IP
strategy leader and value creator for the sixth consecutive year,
having been named in the latest edition of IAM Strategy 300: The
World’s Leading IP Strategists. The IAM Strategy 300 guide is
available at www.iam-media.com/directories/strategy300.
About Titan
Titan Medical Inc. is focused on robotic-assisted technologies
for application in minimally invasive surgery (“MIS”). Titan is
developing a single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a dual-view camera
system with 3D and 2D high-definition vision systems and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an ergonomic interface to the
patient cart and a 3D high-definition endoscopic view of the MIS
procedure. Titan intends to initially pursue gynecologic surgical
indications for use with its single-port robotic surgical
system.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Report on Form 20F dated March 30, 2020 (which may be viewed at
www.sedar.com and at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200917005255/en/
Stephen Randall Chief Financial Officer +1-416-548-7522
stephen@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From May 2023 to May 2024